# Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)

> **NCT01077817** · — · COMPLETED · sponsor: **Organon and Co** · enrollment: 684815 (actual)

## Conditions studied

- Esophageal Cancer
- Squamous Cell Carcinoma
- Adenocarcinoma

## Interventions

- **DRUG:** Alendronate
- **DRUG:** Etidronate
- **DRUG:** Ibandronate
- **DRUG:** Risedronate
- **DRUG:** Raloxifene

## Key facts

- **NCT ID:** NCT01077817
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-26
- **Primary completion:** 2012-02-16
- **Final completion:** 2012-02-16
- **Target enrollment:** 684815 (ACTUAL)
- **Last updated:** 2022-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077817, "Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01077817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*